Daiichi Sankyo's Innovative Drug Delixi (Melogabalin Besylate Tablets) Successfully Launches Commercially in China for Diabetic Peripheral Neuropathic Pain

On October 18, 2024, Delijing, an innovative drug independently developed by Daiichi Sankyo, was officially commercially launched in China for the treatment of Diabetic Peripheral Neuropathic Pain (DPNP) in adults. The launch of this new drug brings high-quality imported original research medication to DPNP patients, meeting the needs of a wide range of patients.

Dyleeze is an important self-developed product by Daiichi Sankyo in the field of primary healthcare, aiming to address current inadequacies in DPNP treatment. As one of the common complications of diabetes, DPNP has long been a focal point in the global medical community. In China, with its large population of diabetes patients, the treatment of diabetic peripheral neuropathic pain (DPNP) has faced the challenge of lacking suitable therapeutic drugs for a long time. The launch of Dyleeze will bring new hope to DPNP patients in China and significantly improve their quality of life.

On October 18, the Delijing product successfully completed its first commercial order. This marks the official launch of Delijing in the Chinese market, bringing a new treatment option to a wide range of patients.

That afternoon, thanks to the efforts of multiple departments at Daiichi Sankyo and the full cooperation with partner distributors, Delijing became available at multiple outlets across Shanghai, Beijing, Guangdong, and Shenyang. This allowed patients to purchase Delijing as soon as it hit the market, benefiting them greatly. This milestone marks the successful launch of Delijing in the Chinese market, bringing hope to more patients.

In the future, we will cover more hospitals and retail markets, providing doctors and patients in China with more effective DPNP treatment options. We believe that with the promotion and application of Delijing, more patients will benefit from it, improving their quality of life.

Let us jointly celebrate the successful launch of Delijing in China, and look forward to providing better and more comprehensive DPNP treatment options for clinical doctors and patients in China!